US 7,452,538 B2 · Death domain containing receptor 4 antibodies and methods

Abstract

The present invention relates to novel Death Domain Containing Receptor-4 (DR4) proteins which are members of the tumor necrosis factor (TNF) receptor family. In particular, isolated nucleic acid molecules are provided encoding the human DR4 proteins. DR4 polypeptides are also provided as are vectors, host cells and recombinant methods for producing the same. The invention further relates to screening methods for identifying agonists and antagonists of DR4 activity and methods for using DR4 polynucleotides and polypeptides. The invention also relates to the treatment of diseases associated with reduced or increased levels of apoptosis using antibodies specific for DR4, which may be agonists and/or antagonists of DR4 activity.

Claims45

Dependent claims

A method for treating cancer comprising administering to an individual therapeutically effective amounts of:

(a) a first therapeutic agent comprising an antibody which binds to a polypeptide selected from the group consisting of:
(i) amino acids 1 to 468 of SEQ ID NO:2;
(ii) amino acids 24 to 468 of SEQ ID NO:2;
(iii) amino acids 24 to 238 of SEQ ID NO:2;
(iv) the amino acid sequence of the full-length polypeptide encoded by the cDNA contained in ATCC Deposit No. 97853;
(v) the amino acid sequence of the mature polypeptide encoded by the cDNA contained in ATCC Deposit No. 97853;
and
(vi) the amino acid sequence of the extracellular domain of the polypeptide encoded by the cDNA contained in ATCC Deposit No. 97853;
and
(b) a second therapeutic agent selected from the group consisting of:
(i) TRAIL;
(ii) a tumor necrosis factor
(iii) a chemotherapeutic agent;
and
(iv) a cytokine.

12 more elements

Dependencies are inferred from the claim text.

Facts

Application

10/648,786Filed 27 Aug 2003 · continuation in part

Priority

28 Jan 1997

Published

US 2004/0136950 A115 Jul 2004

Granted

18 Nov 2008

Term ends

Not estimatedThe source records don’t support an estimate.

Classification12 codes

C07K 16/2878
Against receptors, cell surface antigens or cell surface determinants: against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
A61K 39/39541
Against materials from animals: against normal tissues, cells
C07K 14/70578
Receptors; Cell surface antigens; Cell surface determinants: nGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
C07K 14/7151
For cytokines; for lymphokines; for interferons: for tumor necrosis factor [TNF], for lymphotoxin [LT]

Family

Application60/035,722Us provisional application · filed 28 Jan 1997

Application60/037,829Us provisional application · filed 5 Feb 1997

Application09/013,895Parent of this continuation-in-part · filed 27 Jan 1998

Application60/132,922Us provisional application · filed 6 May 1999

Application09/565,918Parent of this continuation-in-part · filed 5 May 2000

Application60/406,922Us provisional application · filed 30 Aug 2002

Application60/413,861Us provisional application · filed 27 Sep 2002

US 2004/0136950 A1Pre-grant publication · published 15 Jul 2004

US 2005/0112090 A9Pre-grant publication · published 26 May 2005

US 6,433,147 B1Parent of this continuation-in-part

US 6,342,363 B1Parent of this continuation-in-part

US 7,452,538 B2This patent

From the US filing history. Foreign family members aren’t listed.

Death domain containing receptor 4 antibodies and methods

Life of this patent

Death domain containing receptor 4 antibodies and methods

Life of this patent

Abstract

Claims45